You just read:

IMBRUVICA® (ibrutinib) RESONATE™-2 Data Show Significant Improvements in Progression-Free and Overall Survival Versus Chlorambucil in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

News provided by

Janssen Inc.

Dec 08, 2015, 09:13 ET